Genoskin is a cutting-edge brand that has revolutionized drug development by using real human tissue. With a mission to accelerate drug development and help patients faster, they provide first-in-human data without harming humans or animals. Genoskin combines live human data generation platforms, hi-tech machine learning, and unbiased data analysis to deliver the essential data needed to move drug projects forward.

Their range of products and services include R&D services, injection site reactions platform, MANTIS® spatial biology platform, psoriasis research studies, cosmetic claim substantiation, data platforms, and access to their innovative skin models such as NativeSkin®, HypoSkin®, and InflammaSkin®. Since their inception in 2010, Genoskin has continuously strived for ethical science and has been recognized for their groundbreaking work. Their patented NativeSkin® model provides a reliable alternative to animal testing, and they have expanded their skin model range to tackle complex research on human skin.

With a focus on US expansion and hypergrowth, Genoskin has opened offices in Salem, MA and has been recognized as one of the fastest-growing companies in Europe. Their commitment to providing accessible skin models worldwide has led to the development of an online shop and the introduction of NativeSkin access®. Genoskin is dedicated to changing drug development by harnessing the power of first-in-human data, ensuring that more drug projects reach the market and patients receive the treatments they need